Comparative Pharmacology
Head-to-head clinical analysis: ENABLEX versus TOVIAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENABLEX versus TOVIAZ.
ENABLEX vs TOVIAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Darifenacin is a competitive muscarinic receptor antagonist with high affinity for the M3 receptor subtype, which is involved in urinary bladder contraction and salivary secretion. It reduces detrusor muscle overactivity by blocking acetylcholine binding at muscarinic receptors in the bladder.
Competitive antagonist of muscarinic acetylcholine receptors (M1-M5), with high selectivity for M3 receptors, reducing detrusor muscle contractions and bladder overactivity.
7.5 mg to 15 mg orally once daily.
4 mg orally once daily; may increase to 8 mg once daily based on individual response and tolerability.
None Documented
None Documented
13 hours; steady-state achieved within 3-5 days
Terminal elimination half-life of the active metabolite (5-hydroxymethyl tolterodine) is approximately 7-8 hours in extensive CYP2D6 metabolizers and 9-10 hours in poor metabolizers. Clinical context: supports twice-daily dosing for sustained antimuscarinic effect.
Renal (70% as metabolites, <1% unchanged), fecal (20%)
Approximately 18% renal excretion of unchanged drug; major elimination via hepatic metabolism (CYP3A4 and CYP2D6) with subsequent biliary/fecal excretion of metabolites. Fecal excretion accounts for ~60% of total elimination, while urinary excretion is <20% as unchanged fesoterodine or active metabolite.
Category C
Category C
Antimuscarinic
Antimuscarinic